Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900

Alzheimer’s Association Statement Phase III Results for Tarenflurbil (Flurizan)

Alzheimer’s Association Statement Phase III Results for Tarenflurbil (Flurizan)
Share or Print this page
Share or Print this page
June 29, 2008
Share or Print this page

Alzheimer’s Association Statement Phase III Results for Tarenflurbil (Flurizan)

On behalf of people with Alzheimer’s disease, their loved ones and caregivers, the Alzheimer’s Association is disappointed that the results from the Flurizan Phase III trial of an anti-amyloid therapy in Alzheimer’s were negative.  The study did not achieve statistical significance on either of its primary endpoints – cognition and activities of daily living.

Just because the Flurizan Phase III clinical trial failed, doesn’t mean that other amyloid-targeted therapies in the clinical trial pipeline aren’t valid. We learn a great deal from every clinical study. 

We are very pleased to see several compounds now in Phase III clinical trials for Alzheimer’s that represent a variety of treatment strategies. Clinical trials of possible Alzheimer’s therapies raise hope for an emerging new era in treatment of the disease. The odds are quite good that we’ll have more effective new treatments for Alzheimer’s in the near future.

Call to action
Help us change the course
of Alzheimer's disease

Learn what you can do >>

act against alzheimer's

Alzheimer's Association

The Alzheimer's Association is the world's leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit

Keep Up With Alzheimer’s News and Events